October 31, 2025

Notice Regarding the Revision of the Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2026

This is to announce that the consolidated financial forecast for the fiscal year ending March 31, 2026 announced on August 7, 2025 is revised as below.

1. Revision of the Consolidated Financial Forecast

(1) Consolidated Financial Forecast for the First Half of the Year ended September 30, 2025

(From April 1, 2025 to September 30, 2025)

	Revenue	Operating Profit	Profit before Tax	Profit Attributable to Owners of Parent	Basic Earnings per Share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous Forecast (A)	313,000	(8,000)	(6,000)	5,000	15.20
Revised Forecast (B)	313,000	(5,000)	(5,500)	5,000	15.20
Difference (B-A)	0	3,000	500	0	
Change (%)	0.0%	–	–	0.0%	
(Reference) Results of the First Half ended September 30, 2024	332,779	5,817	4,454	2,963	8.55

(2) Consolidated Financial Forecast for the Year ending March 31, 2026 (From April 1, 2025 to March 31, 2026)

	Revenue	Operating Profit	Profit before Tax	Profit Attributable to Owners of Parent	Basic Earnings per Share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous Forecast (A)	700,000	21,000	25,000	27,000	82.08
Revised Forecast (B)	680,000	14,000	16,000	20,000	60.78
Difference (B-A)	(20,000)	(7,000)	(9,000)	(7,000)	
Change (%)	(2.9)%	(33.3)%	(36.0)%	(25.9)%	
(Reference) Results of the Year ended March 31, 2025	715,285	2,422	4,533	6,123	17.86

2. Background of the Revision of Consolidated Financial Forecast

Regarding the consolidated results for the first half ended September 30, 2025, revenue is expected to be generally in line with the forecast on a Company-wide basis, as the underperformance mainly due to the postponement of sales in the Digital Manufacturing Business has been offset by favorable foreign exchange effects in the Imaging Products Business and the Healthcare Business. Operating profit, however, has been revised upward as described in 1. (1) above. This is mainly attributable to the earlier-than-planned recognition of a gain on the transfer of the semiconductor wafer bonding technology R&D business in the Precision Equipment Business, originally scheduled for the second half, as well as other factors such as cost reductions and deferrals in the Healthcare Business and the Components Business, which more than offset the negative impact of the postponement of sales in the Digital Manufacturing Business.

Regarding the consolidated financial forecast for the year ending March 31, 2026, revenue, operating profit, profit before tax, and profit attributable to owners of parent have been revised downward as described in 1. (2) above, due to projected shortfalls in sales in the Precision Equipment Business and the Digital Manufacturing Business.

As for the exchange rate assumptions for the third quarter onward, the Company has revised its previous assumptions of USD1 = JPY145 and EUR1 = JPY155 to USD1 = JPY145 and EUR1 = JPY170.

Forecast in this disclosure is made by management in light of information currently available. A number of factors could cause actual results to differ materially from those disclosed as above.

End of document